Skip to main content

Day: April 8, 2020

BioCryst to Present at 19th Annual Needham Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 10:00 a.m. ET. The conference is being conducted as a virtual conference.Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.About BioCryst PharmaceuticalsBioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930,...

Continue reading

Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

STAMFORD, Conn., April 08, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the virtual 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 10:00 a.m. ET.A live webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.About Cara TherapeuticsCara Therapeutics...

Continue reading

Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, at 11:20a.m. ET.The presentation will be webcast live and may be accessed by visiting the “Investors” section of the Company’s website under the “Events and Presentations” tab at www.nabriva.com. A replay of the webcast will be available for 90 days.About Nabriva Therapeutics plcNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development...

Continue reading

SEARCH MINERALS OUTLINES THE SILVER FOX ZIRCONIUM-RARE EARTH ELEMENT MINERALIZED ZONE, SE LABRADOR

Not for distribution to U.S. Newswire Services or for dissemination in the United States.  Any failure to comply with this restriction may constitute a violation of U.S. securities laws.VANCOUVER, British Columbia, April 08, 2020 (GLOBE NEWSWIRE) — Search Minerals Inc. (TSXV: SMY) (“Search” or the “Company”) is pleased to report assay results from SILVER FOX, its fourth major mineralized zone in its Port Hope Simpson – St. Lewis Critical Rare Earth Element (“CREE”) District. Trenching/channelling (4 new channels in 2019), and mapping/prospecting indicate that the surface expression of this mineralized zone is up to 8.8m wide and 650m long. This surface expression is significantly longer, but thinner, than the surface expressions of the nearby and related FOXTROT and DEEP FOX Resources. The mineralization is similarly hosted by peralkaline...

Continue reading

Hoivatilat Plc: Hoivatilat Plc changes its financial reporting practice

Hoivatilat PlcStock exchange release8 April 2020 at 2 pm EETHoivatilat Plc changes its financial reporting practiceHoivatilat Plc (“Hoivatilat”) will change its financial reporting practice and only publish a half year financial report and a financial statements bulletin in the future. Hoivatilat will therefore not publish the business review for January – March 2020 on 6 May 2020 or the business review for January – September 2020 on 4 November 2020, as previously announced.Aureit Holding Oy (“Aureit Holding”) has acquired through a public tender offer more than 90 per cent of all the issued and outstanding shares and votes in Hoivatilat. Aureit Holding has on 15 January 2020 commenced mandatory redemption proceedings in respect of Hoivatilat’s minority shares by applying for arbitration proceedings to be...

Continue reading

Hoivatilat Oyj: Hoivatilat Oyj muuttaa taloudellisen raportoinnin käytäntöään

Hoivatilat OyjPörssitiedote8.4.2020 klo 14:00 EETHoivatilat Oyj muuttaa taloudellisen raportoinnin käytäntöäänHoivatilat Oyj (“Hoivatilat”) muuttaa taloudellisen raportoinnin käytäntöään ja tulee jatkossa julkaisemaan ainoastaan puolivuosikatsauksen ja tilinpäätöstiedotteen. Näin ollen Hoivatilat ei tule julkaisemaan 6.5.2020 liiketoimintakatsausta ajalta tammi-maaliskuu 2020 eikä 4.11.2020 liiketoimintakatsausta ajalta tammi-syyskuu 2020 kuten aikaisemmin oli ilmoitettu.Aureit Holding Oy (“Aureit Holding”) on hankkinut julkisella ostotarjouksella yli 90 prosenttia kaikista Hoivatilojen liikkeeseen laskemista ja ulkona olevista osakkeista ja äänistä. Aureit Holding on 15.1.2020 käynnistänyt Hoivatilojen vähemmistöosakkeita koskevan lunastusmenettelyn hakemalla välimiesmenettelyn aloittamista osakeyhtiölain 18 luvun...

Continue reading

Horizonte Minerals Plc: FINAL RESULTS FOR YEAR ENDED 31 DECEMBER 2019

LONDON, April 08, 2020 (GLOBE NEWSWIRE) — Horizonte Minerals Plc, (AIM: HZM, TSX: HZM) (‘Horizonte’ or ‘the Company’) the nickel development company focused in Brazil, announces its final results for the year ended 31 December 2019.Full Year HighlightsCompany well-funded to see through current global Covid-19 crisis.  Implemented strict health and safety policies in Brazil and the UK, specifically tailored to Covid-19.Current working structure allows Value Engineering and Project Finance work streams to continue tracking project schedule.In October signed a US$25 million upfront cash royalty agreement with Orion Mine Finance to begin development of the Araguaia project.Awarded the construction licence by SEMAS, the Brazilian Pará State Environmental Agency, for Araguaia permitting construction to begin on...

Continue reading

Cartier Iron Suspends 1000m Diamond Drill Program at Big Easy Gold Project, Newfoundland

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Cartier Iron Corporation (CSE: CFE) (“Cartier Iron”), announces that it has suspended the 1,000m diamond drilling program planned for the Big Easy Gold project located on the Burin Peninsula in eastern Newfoundland. The drill program was designed to test the core of the Central IP chargeability anomaly (see press release March 4, 2020). Hole BE18-30 on the west edge of this anomaly intersected a major new anomalous alteration zone grading 0.11 g Au/t and 2.65 g Ag/t over 180.4m core length (see press release December 20, 2018).The results from the reconnaissance drill program confirmed that the Central chargeability anomaly reflects an extensive zone of low sulphidation epithermal alteration and mineralization that is up to 200m wide with a depth extent of at least 250m (see press release...

Continue reading

Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners

NEEDHAM, Mass., April 08, 2020 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its entry into a revenue interest financing agreement with HealthCare Royalty Partners (HCR) for up to $75 million to support the ongoing development and planned commercial launch of its investigational octreotide capsules product candidate, trade-named MYCAPSSA®, for the maintenance treatment of adults with acromegaly.Under the terms of the agreement, Chiasma will receive $25 million from HCR on April 14, 2020 and is entitled to receive an additional $25 million upon the U.S. Food and Drug Administration (FDA) approval of MYCAPSSA and an additional $15 million upon the availability of commercial drug supply...

Continue reading

ALPHA PRO TECH PROVIDES UPDATE ON PERSONAL PROTECTIVE EQUIPMENT (PPE) ORDERS RESULTING FROM COVID-19 PANDEMIC

NOGALES, Ariz., April 08, 2020 (GLOBE NEWSWIRE) — Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced an update to the status of orders booked for personal protective equipment (PPE) products in APT’s disposable protective apparel product suite, including the company’s proprietary N-95 Particulate Respirator face mask and face shields. As of April 7, 2020, APT has booked approximately $36.7 million in orders for the company’s proprietary N-95 Particulate Respirator face mask since January 27, 2020, an increase of $14.1 million, or 62%, from the $22.6 million in orders reported as of March 11, 2020, and the company continues to experience greater demand.  APT has seen exponential...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.